Cytotoxic T-cell capacity after autologous bone marrow transplantation.
A total of 19 patients, treated for aggressive tumors with high-dose chemo/radiotherapy and autologous bone marrow transplantation (BMT), were studied for concanavalin-A (Con A)-induced proliferation and Con-A-induced cytotoxicity. Ten patients with cytomegalovirus (CMV) antibodies before BMT showed increased Con-A-induced cytotoxicity before and from 100 days after BMT, while Con-A-induced proliferation decreased to less than 10% of control values after BMT and remained so. Nine CMV-negative patients showed normal cytotoxic capacity before and after BMT, while Con-A-induced proliferation recovered slowly from day +30 after BMT. Con-A-induced cytotoxicity was not significantly different between CMV-positive and CMV-negative patients, while Con-A-induced proliferation showed significant differences from day +100 onward.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002277:Carcinoma / Q000276:immunology / Q000628:therapy; D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D003208:Concanavalin A / Q000494:pharmacology; D003587:Cytomegalovirus / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000628:therapy; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D013602:T-Lymphocytes, Cytotoxic / Q000502:physiology*; D013736:Testicular Neoplasms / Q000276:immunology / Q000628:therapy
D000914:Antibodies, Viral; D003208:Concanavalin A